Pharmaceutical giant Mylan continued to draw criticism over the skyrocketing cost of its emergency EpiPen allergy treatment, spurring a rebuke from a large shareholder about the company’s “weak board oversight,” and protests outside of its flagship plant in Morgantown, W.Va., calling for CEO Heather Bresch’s ouster.

In a letter to Mylan’s board of directors, the New York City Pension Funds, which owns approximately 1.1 million Mylan shares, expressed “alarm” with the EpiPen price hikes, and “the risk these actions pose” for the company’s reputation and long-term value.

The letter called for an overhaul of Mylan’s board.

“The EpiPen debacle appears to be the costly consequence of weak board oversight of management decisions that prioritize short-term profit at the expense of long-term value creation,” the letter stated, noting that the fund has had “longstanding concerns” with the board.

Advertise with us

Along with pushing in recent years for a more independent board, the fund has been vocal in its opposition to Mylan’s executive pay packages, which awarded Ms. Bresch nearly $19 million last year.

The life-saving EpiPen auto-injector, which has little competition in the marketplace, has surged some 500 percent in recent years to over $600 a pair, triggering a public backlash and scrutiny by legislators, including an investigation by the U.S. House Oversight and Government Reform Committee.

Mylan has responded by expanding assistance programs and promising to offer a lower-cost generic EpiPen in the coming weeks, but has not moved to cut the price of the brand name product.

On Thursday, protesters gathered outside Mylan’s manufacturing plant in Morgantown with signs pushing for “Human Need over Corporate Greed” and “People over Profit.”

Chants included a call for Ms. Bresch to resign.

Advertise with us

“She’s had a long history of controversy, with her fake degree, with other price issues that they have gotten in trouble for in the past,” rally organizer Andrew Szanto told a local television station, referring to an MBA degree Ms. Bresch had claimed from West Virginia University but did not earn. “We think it would be better, not only for the public, but for the company and its image as well, to be rid of her and the way she’s running the company,” he said.

Mylan did not respond to emails Friday seeking comment.

An investigation launched by WVU following a Post-Gazette story in 2007 found that Ms. Bresch, daughter of then West Virginia governor and now U.S. Senator Joe Manchin, had not earned the MBA degree and that university officials had falsified student records to back up her claim.

The protest in Morgantown came on the heels of a demonstration earlier in the week at Mylan’s executive offices in Cecil led by the watchdog group Public Citizen. The group delivered petitions, signed by more than 700,000 people, demanding an end to the EpiPen “price gouging.”

The outcry over the EpiPen has become the latest flashpoint in a national debate about the escalating cost of prescription drugs.

Advertise with us

On Friday, Hillary Clinton unveiled a plan to protect consumers from “unjustified price hikes” of prescription medications, including the EpiPen.

The plan by the Democratic presidential nominee would create a team of federal officials charged with monitoring drug prices and include efforts to support alternative manufacturers to increase competition and spur innovation.

The plan also would include fines and other penalties to hold drug companies accountable.

Also on Friday, lawmakers pressed Mylan for information about how the company may have shortchanged Medicaid by millions of dollars by underpaying rebates for the EpiPen.

Bloomberg reported Friday that Senator Ron Wyden of Oregon and House Representative Frank Pallone from New Jersey sent a letter to Health and Human Services Secretary Sylvia Mathews Burwell Friday, asking for more details about the drug’s classification and rebate obligations under the Medicaid health program for the poor.

Advertise with us

“Mylan has complied with all laws and regulations regarding the Medicaid rebate classification of EpiPen,” Nina Devlin, a company spokeswoman, said in an e-mail to Bloomberg.

The EpiPen was classified as a “non-innovator” drug, which allows for a lower rebate paid to government programs, before Mylan acquired the product in 2007, Devlin said. Under a new federal rule, Mylan will have to apply to maintain its non-innovator status by April 1, which the company intends to do, she said.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.